Sarah B. Rutter

Sarah B. Rutter

Auto-generated profile, based on publicly available information

Sarah B. Rutter

Department of Psychiatry, Depression and Anxiety Center for Discovery and Treatment, Icahn School of Medicine at Mount Sinai, New York, New York

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
7 July 2022 in Psychological Medicine
Verified
Journal Article
Open access
PDF file
Laurel S. MorrisLaurel S. Morris
Laurel S. Morris
MGMora M. Grehl
Mora M. Grehl
SRSarah B. Rutter
Sarah B. Rutter
MMMarishka Mehta
Marishka Mehta
MWMargaret L. Westwater
Margaret L. Westwater
Motivational processes underlie behaviors that enrich the human experience, and impairments in motivation are commonly observed in psychiatric illness. While motivated behavior is often examined with respect to extrinsic reinforcers, not all actions are driven by reactions to external stimuli; some are driven by ‘intrinsic’ motivation. Intrinsically motivated behaviors are computationally similar to extrinsically motivated behaviors, in that they strive to maximize reward value and minimize punishment. However, our understanding of the neurocognitive mechanisms that underlie intrinsically motivated behavior remains limited. Dysfunction in intrinsic motivation represents an important trans-diagnostic facet of psychiatric symptomology, but due to a lack of clear consensus, the contribution of intrinsic motivation to psychopathology remains poorly understood. This review aims to provide an overview of the conceptualization, measurement, and neurobiology of intrinsic motivation, providing a framework for understanding its potential contributions to psychopathology and its treatment. Distinctions between intrinsic and extrinsic motivation are discussed, including divergence in the types of associated rewards or outcomes that drive behavioral action and choice. A useful framework for understanding intrinsic motivation, and thus separating it from extrinsic motivation, is developed and suggestions for optimization of paradigms to measure intrinsic motivation are proposed.

2 April 2025 in The Journal of Clinical Psychiatry
Verified
Journal Article
Closed access
ADAndrew A. Delgado
Andrew A. Delgado
James W. MurroughJames W. Murrough
James W. Murrough
DSDenise M. Sloan
Denise M. Sloan
DCDennis S. Charney
Dennis S. Charney
RPRobert H. Pietrzak
Robert H. Pietrzak
OBOneysha Brown
Oneysha Brown
Preliminary findings suggest that the combined treatment may yield large and durable symptom reductions for patients with severe chronic PTSD

20 June 2024 in Journal of Contemporary Psychotherapy
Verified
Journal Article
Closed access
PDF file
SRSarah B. Rutter
Sarah B. Rutter

14 April 2021 in medRxiv
Verified
Preprint
Open access
PDF file
ANAgnes Norbury
Agnes Norbury
SRSarah B. Rutter
Sarah B. Rutter
ACAbigail B. Collins
Abigail B. Collins
SCSara Costi
Sara Costi
MJManish K. Jha
Manish K. Jha
AFAdriana Feder
Adriana Feder
Promising initial data indicate that the glutamate N-methyl-D-aspartate (NMDA) receptor antagonist ketamine may be beneficial in post-traumatic stress disorder (PTSD). Here, we explore the neural correlates of ketamine-related changes in PTSD symptoms, using a rich battery of functional imaging data (two emotion-processing tasks and one task-free scan), collected from a subset of participants of a randomized clinical trial of repeated-dose intravenous ketamine vs midazolam (total N =21). In a pre-registered analysis, we tested whether changes in an a priori set of imaging measures from a target neural circuit were predictive of improvement in PTSD symptoms, using leave-one-out cross-validated elastic-net regression models (regions of interest in the target circuit consisted of the dorsal and rostral anterior cingulate cortex, ventromedial prefrontal cortex, anterior hippocampus, anterior insula, and amygdala). Improvements in PTSD severity were associated with increased functional connectivity between the ventromedial prefrontal cortex (vmPFC) and amygdala during emotional face-viewing (change score retained in model with minimum predictive error in left-out subjects, standardized regression coefficient [β]=2.90). This effect was stronger in participants who received ketamine compared to midazolam (interaction β=0.86), and persisted following inclusion of concomitant change in depressive symptoms in the analysis model (β=0.69). Improvement following ketamine was also predicted by decreased dorsal anterior cingulate activity during emotional conflict regulation, and increased task-free connectivity between the vmPFC and anterior insula (βs=-2.82, 0.60). Exploratory follow-up analysis via dynamic causal modelling revealed that whilst improvement in PTSD symptoms following either drug was associated with decreased excitatory modulation of amygdala→vmPFC connectivity during emotional face-viewing, increased top-down inhibition of the amygdala by the vmPFC was only observed in participants who improved under ketamine. Individuals with low prefrontal inhibition of amygdala responses to faces at baseline also showed greater improvements following ketamine treatment. These preliminary findings suggest that, specifically under ketamine, improvements in PTSD symptoms are accompanied by normalization of hypofrontal control over amygdala responses to social signals of threat.